title: New antibiotics against gram-positives: present and future indications.
abstract: Gram-positive cocci are the most frequent aetiology of community and nosocomially bacterial acquired infections. The prevalence of multidrug-resistant gram-positive bacteria is increasing and is associated with high morbidity and mortality. New antibiotics will be available in the European market during the next months. This revision is focused on lipoglycopeptides, new cephalosporins active against methicillin-resistant Staphylococcus aureus (MRSA) and the new oxazolidinone, tedizolid. The purpose of this review is to describe their in vitro activity, pharmacokinetic and pharmacodynamic characteristics, and experience from clinical trials.
authors.affiliation: Department of Infectious Diseases, University of Barcelona, IDIBAPS, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Morata
authors.affiliation: Department of Infectious Diseases, University of Barcelona, IDIBAPS, Spain.
authors.forename: Josep
authors.initials: J
authors.lastname: Mensa
authors.affiliation: Department of Infectious Diseases, University of Barcelona, IDIBAPS, Spain. Electronic address: asoriano@clinic.ub.es.
authors.forename: Alex
authors.initials: A
authors.lastname: Soriano
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use; D006020:Glycopeptides / Q000627:therapeutic use; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000077427:Lipoglycopeptides; D010080:Oxazoles / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010080:Oxazoles; C487637:telavancin